VEGFA and neoplasm: We also performed a Cox regression that included age (>65 years vs. <65 years), sex (M vs. F), tumor stage (II–III vs. IV), performance status (ECOG 0–1 vs. 2–3), Khorana score (<2 vs. ≥2), and treatment (regimens with anti-VEGF agent vs. other) to identify factors that contribute to the development of VTE.